Research Summary

Dr. Brian Schulte is a hematologist-oncologist who cares for patients with sarcomas, rare cancers that develop in connective tissues (such as bone, muscle or cartilage) and can affect people of all ages. Working as part of a multidisciplinary team, he strives to ensure patients receive the best possible comprehensive care. In research, Dr. Schulte studies novel medications, alone and in combination, to treat sarcoma.
After earning a bachelor's degree in engineering at Duke University, Dr. Schulte earned his medical degree at the Medical College of Wisconsin and completed a residency in internal medicine at the University of Colorado Anschutz Medical Campus. He completed a fellowship in hematology-oncology at Northwestern University Feinberg School of Medicine, where he served as chief fellow.

Education

10/2021 - Diversity, Equity, and Inclusion Champion Training, University of California
06/2021 - Hematology/Oncology, Northwestern University
06/2018 - Internal Medicine, University of Colorado
MD, 05/2015 - , Medical College of Wisconsin
BSE, 05/2009 - Biomedical Engineering, Duke University

Honors & Awards

  • Sarcoma Immunotherapy Initiative Clinical Champion, UCSF, 2023-pres
  • Chief Fellow Hematology/Oncology, Northwestern University, 2019-2020
  • Alpha Omega Alpha, 2014

Selected Publications

  1. Neiman ZM, Legasto CS, Chin AK, Guan T, Schulte BC Utilization of dexrazoxane in patients treated with doxorubicin: a retrospective, propensity matched analysis of cardiac function and toxicity.  View on PubMed
  2. Schulte BC, Hwang C, Horvai AE, Olivier T. When destiny doesn't pan out: Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan. Cancer. 2024 Dec 01; 130(23):4020-4024.  View on PubMed
  3. Schulte B, Mach N, Olivier T. Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcomas: Looking Forward to What Is Next. J Clin Oncol. 2024 Jul 10; 42(20):2488.  View on PubMed
  4. Hwang C, Agulnik M, Schulte B. Prices and Trends in FDA-Approved Medications for Sarcomas. Cancers (Basel). 2024 Apr 18; 16(8).  View on PubMed
  5. Schulte B. Considerations for Prompting Large Language Models. JAMA Oncol. 2024 Apr 01; 10(4):538.  View on PubMed
  6. Pandita D, Dave M, Schulte B. PD-1 Inhibition in metastatic high tumour mutational burden (TMB) leiomyosarcoma with clinicopathological correlates. BMJ Case Rep. 2023 Nov 17; 16(11).  View on PubMed
  7. Alhaja M, Chen S, Chin AC, Schulte B, Legasto CS. Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer. Cureus. 2023 Sep; 15(9):e44837.  View on PubMed
  8. Schulte B. Capacity of ChatGPT to Identify Guideline-Based Treatments for Advanced Solid Tumors. Cureus. 2023 Apr; 15(4):e37938.  View on PubMed
  9. Fuchs JW, Schulte BC, Fuchs JR, Agulnik M. Targeted therapies for the treatment of soft tissue sarcoma. Front Oncol. 2023; 13:1122508.  View on PubMed
  10. Fuchs JR, Schulte BC, Fuchs JW, Agulnik M. Emerging targeted and cellular therapies in the treatment of advanced and metastatic synovial sarcoma. Front Oncol. 2023; 13:1123464.  View on PubMed
  11. Zhang S, Black RG, Kohli K, Hayes BJ, Miller C, Koehne A, Schroeder BA, Abrams K, Schulte BC, Alexiev BA, Heimberger AB, Zhang A, Jing W, Ng JCK, Shinglot H, Seguin B, Salter AI, Riddell SR, Jensen MC, Gottschalk S, Moore PF, Torok-Storb B, Pollack SM. B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model. Mol Cancer Ther. 2022 06 01; 21(6):999-1009.  View on PubMed
  12. Schroeder BA, LaFranzo NA, LaFleur BJ, Gittelman RM, Vignali M, Zhang S, Flanagan KC, Rytlewski J, Riolobos L, Schulte BC, Kim TS, Chen E, Smythe KS, Wagner MJ, Mantilla JG, Campbell JS, Pierce RH, Jones RL, Cranmer LD, Pollack SM. CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes. J Immunother Cancer. 2021 08; 9(8).  View on PubMed
  13. Agulnik M, Schulte B, Robinson S, Hirbe AC, Kozak K, Chawla SP, Attia S, Rademaker A, Zhang H, Abbinanti S, Cehic R, Monga V, Milhem M, Okuno S, Van Tine BA. An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma. Eur J Cancer. 2021 09; 154:201-208.  View on PubMed
  14. Principe DR, Schulte BC, Kamath SD, Munshi HG. Glandular metastases from renal cell carcinoma show poor clinical responses to immune checkpoint inhibition but durable responses to angiogenesis inhibitors. BMJ Case Rep. 2021 Jun 22; 14(6).  View on PubMed
  15. Schulte B, Mohindra N, Milhem M, Attia S, Robinson S, Monga V, Hirbe AC, Oppelt P, Charlson J, Helenowski I, Abbinanti S, Cehic R, Okuno S, Van Tine BA, Agulnik M. Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. Br J Cancer. 2021 08; 125(4):528-533.  View on PubMed
  16. Lambden JP, Kelsten MF, Schulte BC, Abbinanti S, Hayes JP, Villaflor V, Agulnik M. Metastatic Myxofibrosarcoma with Durable Response to Temozolomide Followed by Atezolizumab: A Case Report. Oncologist. 2021 07; 26(7):549-553.  View on PubMed
  17. Schulte B, Morgans AK, Shore ND, Pezaro C. Sorting Through the Maze of Treatment Options for Metastatic Castration-Sensitive Prostate Cancer. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-10.  View on PubMed
  18. Zhang W, Jordan KR, Schulte B, Purev E. Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system. Drug Des Devel Ther. 2018; 12:3343-3356.  View on PubMed
  19. Schulte BC, Wu W, Rosen T. Azelaic Acid: Evidence-based Update on Mechanism of Action and Clinical Application. J Drugs Dermatol. 2015 Sep; 14(9):964-8.  View on PubMed
  20. Wu X, Schulte BC, Zhou Y, Haribhai D, Mackinnon AC, Plaza JA, Williams CB, Hwang ST. Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo. J Invest Dermatol. 2014 Nov; 134(11):2814-2822.  View on PubMed

Go to UCSF Profiles, powered by CTSI